|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.9%
25.97
2,597
USD
|
100
-0.9%
|
25.97
|
2,597
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.9%
26.98
2,698
USD
|
100
-0.9%
|
26.98
|
2,698
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.9%
27.05
2,705
USD
|
100
-0.9%
|
27.05
|
2,705
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
200
-1.7%
27.02
5,404
USD
|
200
-1.7%
|
27.02
|
5,404
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.9%
26.99
2,699
USD
|
100
-0.9%
|
26.99
|
2,699
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.8%
26.97
2,697
USD
|
100
-0.8%
|
26.97
|
2,697
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.8%
26.88
2,688
USD
|
100
-0.8%
|
26.88
|
2,688
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.8%
26.68
2,668
USD
|
100
-0.8%
|
26.68
|
2,668
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
92
-0.8%
26.53
2,441
USD
|
92
-0.8%
|
26.53
|
2,441
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.8%
26.60
2,660
USD
|
100
-0.8%
|
26.60
|
2,660
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.8%
26.47
2,647
USD
|
100
-0.8%
|
26.47
|
2,647
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.8%
26.33
2,633
USD
|
100
-0.8%
|
26.33
|
2,633
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.8%
26.15
2,615
USD
|
100
-0.8%
|
26.15
|
2,615
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
200
-1.6%
26.13
5,226
USD
|
200
-1.6%
|
26.13
|
5,226
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.8%
26.14
2,614
USD
|
100
-0.8%
|
26.14
|
2,614
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
200
-1.5%
26.16
5,232
USD
|
200
-1.5%
|
26.16
|
5,232
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.8%
25.98
2,598
USD
|
100
-0.8%
|
25.98
|
2,598
USD
|
|
|
2009-01-06 |
2009-01-02 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.8%
25.92
2,592
USD
|
100
-0.8%
|
25.92
|
2,592
USD
|
|
|
2008-12-03 |
2008-12-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
29.67
2,967
USD
|
100
-0.1%
|
29.67
|
2,967
USD
|
|
|
2008-12-03 |
2008-12-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
29.54
2,954
USD
|
100
-0.1%
|
29.54
|
2,954
USD
|
|
|
2008-12-03 |
2008-12-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
29.40
2,940
USD
|
100
-0.1%
|
29.40
|
2,940
USD
|
|
|
2008-12-03 |
2008-12-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
29.07
2,907
USD
|
100
-0.1%
|
29.07
|
2,907
USD
|
|
|
2008-12-03 |
2008-12-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
200
-0.2%
29.64
5,928
USD
|
200
-0.2%
|
29.64
|
5,928
USD
|
|
|
2008-12-03 |
2008-12-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
31.11
3,111
USD
|
100
-0.1%
|
31.11
|
3,111
USD
|
|
|
2008-12-03 |
2008-12-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
28.88
2,888
USD
|
100
-0.1%
|
28.88
|
2,888
USD
|
|
|
2008-12-03 |
2008-12-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
29.67
2,967
USD
|
100
-0.1%
|
29.67
|
2,967
USD
|
|
|
2008-12-03 |
2008-12-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
30.86
3,086
USD
|
100
-0.1%
|
30.86
|
3,086
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-1.0%
41.72
4,172
USD
|
100
-1.0%
|
41.72
|
4,172
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-1.0%
41.83
4,183
USD
|
100
-1.0%
|
41.83
|
4,183
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-1.0%
41.85
4,185
USD
|
100
-1.0%
|
41.85
|
4,185
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.9%
41.56
4,156
USD
|
100
-0.9%
|
41.56
|
4,156
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.9%
42.20
4,220
USD
|
100
-0.9%
|
42.20
|
4,220
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.9%
42.88
4,288
USD
|
100
-0.9%
|
42.88
|
4,288
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.9%
42.66
4,266
USD
|
100
-0.9%
|
42.66
|
4,266
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.9%
42.90
4,290
USD
|
100
-0.9%
|
42.90
|
4,290
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.9%
41.12
4,112
USD
|
100
-0.9%
|
41.12
|
4,112
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Cundy Kenneth C
SVP, Preclinical Development
Officer
|
100
-0.9%
41.43
4,143
USD
|
100
-0.9%
|
41.43
|
4,143
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
42.90
4,290
USD
|
100
-0.1%
|
42.90
|
4,290
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.12
4,112
USD
|
100
-0.1%
|
41.12
|
4,112
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
42.57
4,257
USD
|
100
-0.1%
|
42.57
|
4,257
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.93
4,193
USD
|
100
-0.1%
|
41.93
|
4,193
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.85
4,185
USD
|
100
-0.1%
|
41.85
|
4,185
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.43
4,143
USD
|
100
-0.1%
|
41.43
|
4,143
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.77
4,177
USD
|
100
-0.1%
|
41.77
|
4,177
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.60
4,160
USD
|
100
-0.1%
|
41.60
|
4,160
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.74
4,174
USD
|
100
-0.1%
|
41.74
|
4,174
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
42.11
4,211
USD
|
100
-0.1%
|
42.11
|
4,211
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
42.23
4,223
USD
|
100
-0.1%
|
42.23
|
4,223
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
42.20
4,220
USD
|
100
-0.1%
|
42.20
|
4,220
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
42.46
4,246
USD
|
100
-0.1%
|
42.46
|
4,246
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
42.82
4,282
USD
|
100
-0.1%
|
42.82
|
4,282
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
42.90
4,290
USD
|
100
-0.1%
|
42.90
|
4,290
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
42.88
4,288
USD
|
100
-0.1%
|
42.88
|
4,288
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
42.92
4,292
USD
|
100
-0.1%
|
42.92
|
4,292
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
37
-0.0%
42.66
1,578
USD
|
37
-0.0%
|
42.66
|
1,578
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.13
4,113
USD
|
100
-0.1%
|
41.13
|
4,113
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
63
-0.1%
42.64
2,686
USD
|
63
-0.1%
|
42.64
|
2,686
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.43
4,143
USD
|
100
-0.1%
|
41.43
|
4,143
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.12
4,112
USD
|
100
-0.1%
|
41.12
|
4,112
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
42.89
4,289
USD
|
100
-0.1%
|
42.89
|
4,289
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.43
4,143
USD
|
100
-0.1%
|
41.43
|
4,143
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.82
4,182
USD
|
100
-0.1%
|
41.82
|
4,182
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.83
4,183
USD
|
100
-0.1%
|
41.83
|
4,183
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.93
4,193
USD
|
100
-0.1%
|
41.93
|
4,193
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.77
4,177
USD
|
100
-0.1%
|
41.77
|
4,177
USD
|
|
|
2008-11-05 |
2008-11-03 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
41.75
4,175
USD
|
100
-0.1%
|
41.75
|
4,175
USD
|
|
|
2008-10-03 |
2008-10-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
48.91
4,891
USD
|
100
-0.1%
|
48.91
|
4,891
USD
|
|
|
2008-10-03 |
2008-10-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
48.75
4,875
USD
|
100
-0.1%
|
48.75
|
4,875
USD
|
|
|
2008-10-03 |
2008-10-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
48.46
4,846
USD
|
100
-0.1%
|
48.46
|
4,846
USD
|
|
|
2008-10-03 |
2008-10-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
48.75
4,875
USD
|
100
-0.1%
|
48.75
|
4,875
USD
|
|
|
2008-10-03 |
2008-10-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
48.87
4,887
USD
|
100
-0.1%
|
48.87
|
4,887
USD
|
|
|
2008-10-03 |
2008-10-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
48.89
4,889
USD
|
100
-0.1%
|
48.89
|
4,889
USD
|
|
|
2008-10-03 |
2008-10-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
48.64
4,864
USD
|
100
-0.1%
|
48.64
|
4,864
USD
|
|
|
2008-10-03 |
2008-10-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
47.93
4,793
USD
|
100
-0.1%
|
47.93
|
4,793
USD
|
|
|
2008-10-03 |
2008-10-01 |
PS
Planned sale
|
Gallop Mark A
SVP, Research
Officer
|
100
-0.1%
48.99
4,899
USD
|
100
-0.1%
|
48.99
|
4,899
USD
|
|
